Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic impact for metabolic disease
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic impact for metabolic disease. / Finan, Brian; Clemmensen, Christoffer; Zhu, Zhimeng; Stemmer, Kerstin; Gauthier, Karine; Müller, Luisa; De Angelis, Meri; Moreth, Kristin; Neff, Frauke; Perez-Tilve, Diego; Fischer, Katrin; Lutter, Dominik; Sánchez-Garrido, Miguel A.; Liu, Peng; Tuckermann, Jan; Malehmir, Mohsen; Healy, Marc E.; Weber, Achim; Heikenwalder, Mathias; Jastroch, Martin; Kleinert, Maximilian; Jall, Sigrid; Brandt, Sara; Flamant, Frédéric; Schramm, Karl Werner; Biebermann, Heike; Döring, Yvonne; Weber, Christian; Habegger, Kirk M; Keuper, Michaela; Gelfanov, Vasily; Liu, Fa; Köhrle, Josef; Rozman, Jan; Fuchs, Helmut; Gailus-Durner, Valérie; Hrabě de Angelis, Martin; Hofmann, Susanna M; Yang, Bin; Tschöp, Matthias H; Dimarchi, Richard; Müller, Timo D.
I: Cell, Bind 167, Nr. 3, 2016, s. 843-857.e1-e14.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic impact for metabolic disease
AU - Finan, Brian
AU - Clemmensen, Christoffer
AU - Zhu, Zhimeng
AU - Stemmer, Kerstin
AU - Gauthier, Karine
AU - Müller, Luisa
AU - De Angelis, Meri
AU - Moreth, Kristin
AU - Neff, Frauke
AU - Perez-Tilve, Diego
AU - Fischer, Katrin
AU - Lutter, Dominik
AU - Sánchez-Garrido, Miguel A.
AU - Liu, Peng
AU - Tuckermann, Jan
AU - Malehmir, Mohsen
AU - Healy, Marc E.
AU - Weber, Achim
AU - Heikenwalder, Mathias
AU - Jastroch, Martin
AU - Kleinert, Maximilian
AU - Jall, Sigrid
AU - Brandt, Sara
AU - Flamant, Frédéric
AU - Schramm, Karl Werner
AU - Biebermann, Heike
AU - Döring, Yvonne
AU - Weber, Christian
AU - Habegger, Kirk M
AU - Keuper, Michaela
AU - Gelfanov, Vasily
AU - Liu, Fa
AU - Köhrle, Josef
AU - Rozman, Jan
AU - Fuchs, Helmut
AU - Gailus-Durner, Valérie
AU - Hrabě de Angelis, Martin
AU - Hofmann, Susanna M
AU - Yang, Bin
AU - Tschöp, Matthias H
AU - Dimarchi, Richard
AU - Müller, Timo D
N1 - CURIS 2016 NEXS 400
PY - 2016
Y1 - 2016
N2 - Glucagon and thyroid hormone (T3) exhibit therapeutic potential for metabolic disease but also exhibit undesired effects. We achieved synergistic effects of these two hormones and mitigation of their adverse effects by engineering chemical conjugates enabling delivery of both activities within one precisely targeted molecule. Coordinated glucagon and T3 actions synergize to correct hyperlipidemia, steatohepatitis, atherosclerosis, glucose intolerance, and obesity in metabolically compromised mice. We demonstrate that each hormonal constituent mutually enriches cellular processes in hepatocytes and adipocytes via enhanced hepatic cholesterol metabolism and white fat browning. Synchronized signaling driven by glucagon and T3 reciprocally minimizes the inherent harmful effects of each hormone. Liver-directed T3 action offsets the diabetogenic liability of glucagon, and glucagon-mediated delivery spares the cardiovascular system from adverse T3 action. Our findings support the therapeutic utility of integrating these hormones into a single molecular entity that offers unique potential for treatment of obesity, type 2 diabetes, and cardiovascular disease.
AB - Glucagon and thyroid hormone (T3) exhibit therapeutic potential for metabolic disease but also exhibit undesired effects. We achieved synergistic effects of these two hormones and mitigation of their adverse effects by engineering chemical conjugates enabling delivery of both activities within one precisely targeted molecule. Coordinated glucagon and T3 actions synergize to correct hyperlipidemia, steatohepatitis, atherosclerosis, glucose intolerance, and obesity in metabolically compromised mice. We demonstrate that each hormonal constituent mutually enriches cellular processes in hepatocytes and adipocytes via enhanced hepatic cholesterol metabolism and white fat browning. Synchronized signaling driven by glucagon and T3 reciprocally minimizes the inherent harmful effects of each hormone. Liver-directed T3 action offsets the diabetogenic liability of glucagon, and glucagon-mediated delivery spares the cardiovascular system from adverse T3 action. Our findings support the therapeutic utility of integrating these hormones into a single molecular entity that offers unique potential for treatment of obesity, type 2 diabetes, and cardiovascular disease.
KW - co-agonist
KW - conjugate
KW - dyslipidemia
KW - glucagon
KW - NASH
KW - obesity
KW - polypharmacology
KW - thyroid hormone
U2 - 10.1016/j.cell.2016.09.014
DO - 10.1016/j.cell.2016.09.014
M3 - Journal article
C2 - 27720451
VL - 167
SP - 843-857.e1-e14
JO - Cell
JF - Cell
SN - 0092-8674
IS - 3
ER -
ID: 178892182